12,372 trials
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Greater Than (>) the Cut-off — 64; 20 Participants
Generalized Pustular Psoriasis (GPP) · Adalimumab · Japanese
Primary: Proportion of Participants Achieving Clinical Response at Week 16 — 7 Participants
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — 4.94; 0.99; -65.35; -69.05 percent change — p=<0.0001
Aspergillosis
Primary: Number of Participants With an Adverse Event — 15; 6; 57; 27 Participants
Immune Thrombocytopenic Purpura
Primary: Number of Participants With Stable Platelet Response (Count of ≥50,000/µL on at Least 4 of the Last 6 Scheduled Visits Between Weeks 14 and 24) — 9; 0 Participants…
Hemophilia A
Primary: Mean Annualized Bleed Rate (ABR) by Treatment: On Demand Cohort — 47.0; 1.5 Bleeds per year — p=0.0020
Critical Illness
Primary: Mean Arterial Pressure — 82.8; 80.9; 81.7; 77.6 mm Hg — p=0.385
Type 2 Diabetes
Primary: Disposition Index — 0.023; 0.149 index
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score at Week 12 — -0.77; -1.28 Unit on scale — p=0.7191
Actinic Keratosis
Primary: Number of Subjects With Complete Clearance of AK Lesions — 30.2; 25.7; 9.5 percentage of participants — p=<0.0001
Opioid Use Disorder
Primary: Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection — 57; 51; 57 Participants — p=0.940
Acute Post-surgical Pain
Primary: Sum of Pain Intensity Differences (SPID) — -139.12; -109.08; -103.69; -74.55 units on a scale
Melanoma
Primary: Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) — 15.1; 17.0 Percent of…
Cystic Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 — 0.5; 0.2 Percent predicted of FEV1 — p== 0.5846
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — 13.3; 9.9 Months